Loading...
Complement Inhibition for the Treatment of Myasthenia Gravis
Generalized myasthenia gravis (gMG) is a rare autoimmune disorder affecting the neuromuscular junction (NMJ). Approximately 80–90% of patients display antibodies directed against the nicotinic acetylcholine receptor (AChR). A major drive of AChR antibody-positive MG pathology is represented by compl...
Na minha lista:
| Udgivet i: | Immunotargets Ther |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7751298/ https://ncbi.nlm.nih.gov/pubmed/33365280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S261414 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|